Pfizer and BioNTech announced an analysis that showed that their three-dose coronavirus vaccine regimen indicated a strong immune response in children 6 months to 5 years of age.
The analysis reported an efficacy rate of more than 80 percent, and what this could mean for the future of vaccinating toddlers.
